Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-04-20

Clinical Trial Update: A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

Phase IIa study of TAS-205 for Duchenne Muscular Dystrophy has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAS-205 (TAS-205)

Snippet

Sponsor: Taiho Pharmaceutical Co., Ltd. | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2020-04-20